Oncotype DX tumor gene expression profiling in stage II colon cancer. Application: prognostic, risk prediction.
Overall five-year survival for patients with stage-II colon cancer averages 75% after surgery alone. However, some of these patients have poorer outcomes, similar to patients with stage-III disease. The proposed use of the Oncotype DX assay is to improve risk stratification for recurrence in stage-II colon cancer.
Webber
Elizabeth M
EM
Kaiser Permanente Center for Health Research.
Lin
Jennifer S
JS
Evelyn P Whitlock